Top Markets
#1 Pleasing Gold Pleasing Gold +1,543.14%
#2 PulseChain PulseChain +57.40%
#3 Ontology Gas Ontology Gas +36.19%
#4 Merlin's Seal BTC Merlin's Seal BTC +31.77%
#5 BOOK OF MEME BOOK OF MEME +30.30%
#6 Collect on Fanable Collect on Fanable +24.02%
#7 Neiro Neiro +20.79%
#8 Unit Pump Unit Pump +20.03%
#9 Pump.fun Pump.fun +20.03%
#10 Nockchain Nockchain +19.80%
Coin of the day
Pleasing Gold Pleasing Gold
Settings
Language
ENGLISH
Currency
USD
Theme
Alimera Sciences, Inc. Alimera Sciences, Inc.

Alimera Sciences, Inc.

ALIM
Rank in Stocks #26668
Alimera Sciences, Inc. is a pharmaceutical company focused on developing and... Alimera Sciences, Inc. is a pharmaceutical company focused on developing and commercializing ophthalmic treatments globally, including in the United States. Its primary offering, ILUVIEN, is an intravitreal implant used to manage diabetic macular edema (DME), a severe retinal disease in individuals with diabetes that can lead to profound vision loss and blindness. Additionally, ILUVIEN helps prevent relapses of recurrent non-infectious uveitis affecting the posterior segment of the eye. The company distributes its products directly and through distributors to various healthcare entities such as physician offices, pharmacies, and hospitals. Alimera also maintains a collaboration with EyePoint Pharmaceuticals US, Inc. focused on developing and marketing insert technology. This technology is designed to deliver corticosteroids to the back of the eye for treating and preventing various human eye diseases, including diabetic macular edema. Founded in 2003, Alimera Sciences is headquartered in Alpharetta, Georgia.
Share Price
$5.54
Last synced: 2024-09-18
Market Cap
$38.76M
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade Alimera Sciences, Inc. (ALIM)

Category

Healthcare
Revenue for Alimera Sciences, Inc. (ALIM)
Revenue in Jun 2024 TTM: $99.68M
According to Alimera Sciences, Inc. latest financial reports the company's current revenue (TTM) is $99.68M. In 2022 the company made a revenue of $54.13M a decrease compared to the revenue in the year 2021 that was $59.03M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Alimera Sciences, Inc. from 2006 to 2026
Revenue at the end of each year
Year Revenue Change
2026 (TTM) $99.68M 23.44%
2023 $80.75M 49.19%
2022 $54.13M -8.30%
2021 $59.03M 16.15%
2020 $50.82M -5.79%
2019 $53.94M 14.85%
2018 $46.97M 30.79%
2017 $35.91M 4.60%
2016 $34.33M 53.01%
2015 $22.44M 166.39%
2014 $8.42M 349.95%
2013 $1.87M 0.00%
2012 0.00 0.00%
2011 0.00 0.00%
2010 0.00 0.00%
2009 0.00 0.00%
2008 0.00 0.00%
2007 0.00 0.00%
2006 0.00 0.00%
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
MERCK Kommanditgesellschaft auf Aktien MERCK Kommanditgesellschaft auf Aktien
MERCK Kommanditgesellschaft auf Aktien
MER.SW
 - -
DE
Merck KGaA Merck KGaA
Merck KGaA
MRK.DE
 - -
DE
Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited
4502.T
 - -
JP
Galderma Group AG Galderma Group AG
Galderma Group AG
GALD.SW
 - -
CH
Sun Pharmaceutical Industries Limited Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited
SUNPHARMA.NS
 $6.61B 6,532.81%
IN